Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for various executives following the re-investment of dividends paid on April 10, 2014. The transaction price was 1581.50 pence per Ordinary Share and $53.42 per ADS. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of deferred annual bonus holdings that vest following the end of the relevant measurement period.
Key Facts for Investor Verification
- The filing discloses share acquisitions by executives including Sir Andrew Witty, Dr M M Slaoui, and Dr P J T Vallance under a deferred bonus plan.
- Transactions occurred on April 15, 2014, based on dividend reinvestment at a price of 1581.50 pence per Ordinary Share.
- This document is a regulatory notification under Disclosure and Transparency Rule 3.1.4R(1)(a) and does not contain financial results.